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Tallimustine in advanced previously untreated colorectal cancer, a phase II 
study
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Summary Tulliitiustine is a novel benzoyl mustard derivative from disUtmycin A with a unique mode o f  
action, It  is a D N A  minor groove binder and produces highly sequence-specific alkykuions. Previous studies 
have shown significant anti-tumour effects in animal models. We performed a phase U study in previously
untreated patients with advanced colorectal cancer, using a schedule o f  i»v. bolus infusions of 900 jug m .2 once
every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. 
Toxicity mainly consisted of u highly selective neutropenia, which warrants further investigation of this agent in 
combination with myeloid growth factors,
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Tallimustine is a synthetic derivative of the antiviral 
distamycin A, in which a formyl group at the N-terminal 
position has been replaced by an alkylating benzoyl mustard 
moiety (Arcamone et aL, 1989). Although its mechanism of 
action is not precisely known, its anti-tumour activity has 
been attributed to a very limited number of highly sequence- 
specific alkylations of DNA (Broggini et al„ 1995). 
Tallimustine binds preferentially to adenine-thymine rich 
sequences in the minor groove of DNA, inhibits the binding 
of transcription factors that recognise these sequences and 
specifically inhibits DNA ligase. Unlike classic alkylating 
agents it does not alkylate guanine N7 but only adenine N3 
(Broggini et a l 1991; Coley et al., 1993, Monteeuceo et aL, 
1991). Furthermore, it has immunomodulating properties in 
that it augments T-cell-dependent antibody production 
(Riganti et al,, 1992). It displays potent anti-tumour effects 
on human and murine tumour cell lines as well as on murine 
transplated solid tumours and human tumour xenografts 
(Arcamone et aL> 1989; Giuliani et al., 1988; Pczzoni et al,, 
1991). Tallimustine is cross-resistant with doxorubicin but 
not with melphalan and cisplatin, and drug resistance is only 
partially mediated through mdr-l-p}70 (Pezzoni et a i y 1991; 
Geroni et al., 1993; Capolongo et al„ 1993), The dose- 
limiting toxicity in phase I studies was a highly selective 
neutropenia (Sessa et al., 1994; Abigcrges et al., 1993; 
Hageboutros et a l , 1994). In these studies clinical responses 
were documented in mesothelioma, ethmoid adenocarcinoma 
and ovarian cystadenocarcinoma, Given the paucity of active 
agents in patients with advanced colorectal cancer, we 
initiated a phase II study in previously untreated patients 
to determine the anti-tumour activity of this new agent.
Patients and methods
Inclusion criteria included histologically documented un re­
sectable advanced or metastatic colorectal cancer, no prior 
systemic treatment with the exception of adjuvant chemother­
apy more than 12 months prior to entry, measurable disease 
parameter(s), no prior radiotherapy on all disease para­
meters, age ^18 and ^70 years, ECOG performance status 
^2, life expectancy ^3  months, WBC > 4x lO l)~'' 1, 
granulocytes > 2 x l 0 9~' 1, platelets ^lOOxlQ9" 1 1, serum
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bilirubin < l , 5 m g d l " \  alkaline phosphatase, ASAT, and 
ALAT < 2 x upper limit of normal (in case of liver 
metastases <5x) ,  no signs of brain metastascs, no active 
infections, no second malignancy (with the exception of 
adequately treated in situ carcinoma of the cervix or 
squamous cell carcinoma of the skin), no pregnant or 
breastfeeding women, and written or oral witnessed 
informed consent.
Tallimustine (FCE 24517, Pharmacia, Milan, Italy) was
administered at 900 /tg nr 2 as an i,v, bolus infusion over 3.
5 min, once every 4 weeks. Patients were followed weekly for 
toxicity and every two cycles for response, Full blood counts 
were determined weekly and twice weekly in the third week of 
treatment. Toxicity and response were evaluted according to 
CTC and WHO criteria respectively. Treatment was only 
continued after 4 weeks when neutrophil and platelet counts 
were normal (grade 0), When treatment was postponed or, in 
the case of neutrophil nadir grade 4 for >7 days or <7 days 
but accompanied by fever > 38,5'X\ the dose in the 
subsequent cycle was reduced by 25%. The use of colony- 
stimulating factors was prohibited, No anti-cmetic prophy­
laxis was given during the first cycle, but was allowed in 
following cycles when clinically indicated. Patients with 
progressive disease after two cycles were taken off study, 
and patients with stable disease received a minimum of four 
cycles, A two-stage design of the study was used in order to 
permit termination of the study when no responses were 
documented in the first group of 14 patients.
Results
Seventeen patients were entered into the study. Patient 
characteristics are shown in Table I. Patients received a
median of two ( I ..4) cycles, the total number of administered
cycles was 34. Three patients were not evaluable for response: 
one patient refused further treatment after one cycle, one 
patient was taken off study after one cycle as a result of the 
development of a pelvic abscess and (istulae, one patient died 
after the second cycle before tumour evaluation had been 
performed. Of the 14 patients who were evaluable for 
response, 13 had progressive disease after a median of two 
(1-4) cycles, and one patient with stable disease after two 
cycles refused further treatment (total response rate 0 %, 95% 
confidence interval 0^23%). Toxicity mainly consisted of 
neutropenia (Table II). A total of 13 (76%) patients 
experienced grade 11 I/I V leucocytopenia and/or neutropenia 
during 21 (62%) cycles. Three patients developed febrile 
episodes during neutropenia that resulted in hospital
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Table I Patients’ characteristics
M ¿lie/female
Median age (years) (range)
Median ECOG performance status (range) 
Localisation of primary tumour 
Colon
Rectosigmoid
Rectum
Localisation of metastatic disease 
Liver 
Lung
Lymph nodes
Local recurrence 
Other
Median number of metastatic sites 
Previous treatments 
Surgery 
Radio tli crapy 
Adjuvant chemotherapy 
None
13/4 
58 (43-66) 
I (0 - 2)
9
2
6
12
2
4
2
6
I (1 -3 )
16
4
1
1
Table II Toxicity o f  treatment
Toxic it vm II
Grade
III IV
Leucoeytopenia 4 6 4
Neutropenia 1 1 12
Thrombocytopenia 1 0 0
Anaemia 4 2 0
Infection 0 0 3
Nausea“ 1 2 0
Vomiting11 2 1 0
Anorexia 2 2 0
Diarrhoea 1 1 0
Fatigue I 2 0
Numbers are patients, maximum toxicity per patient is given.
Toxicity according to CTC criteria. llN o  prophylactic antiemetics were 
administered during the first cycle.
Numbers are patients.
admissions for treatment with i.v. antibiotics. Grade IV 
neutropenia occurred between days 13 and 17 after the start 
of treatment and had a median duration of 4 (range 2-9) 
days. Of the 14 patients who received at least two cycles, 
toxicity-related, dose reductions and treatment delays were 
performed in one (7%) and two (14%) patients respectively. 
In these 14 patients no cumulative effect on bone marrow 
toxicity was seen. Platelet toxicity occurred in only one 
patient (grade 2). One patient developed symptoms of arterial 
insufficiency of the left leg together with hypotension and 
anuria 13 days after the second administration of tallimus­
tine. He also had afebrile grade IV neutropenia, which lasted 
only 2 days. Despite vigourous treatment with anticoagu­
lants, pressor agents and i.v. antibiotics he died 11 days later 
as a result of thromboembolic complications resulting in 
multiorgan failure, confirmed by autopsy. A relation with 
tallimustine was thought unlikely,
Discussion
Tallimustine appears to be an attractive cytotoxic agent 
because of its unique mechanism of action, its potent 
preclinical anti-turn our activity in vitro  and in vivo and its 
lack of non-haematological toxicity. However, we found no 
activity in patients with advanced colorectal cancer. Studies 
in other types of cancer are ongoing. Toxicity consisted of a 
highly selective neutropenia, which confirms the data 
obtained from phase I studies (Sessa et cil.H 1994; Abigerges 
et a l.t 1993; Hageboutros et a i 1994). A concentration- 
dependent inhibition of human myeloid progenitor cells has 
been demonstrated (Volpe et a i , 1993). The striking absence 
of platelet toxicity as well as the low incidence of manageable 
non-haematological toxicities makes this agent a very 
attractive candidate for combination with myeloid growth 
factors.
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